Advertiment
The U.S. Food and Drug Administration has expanded approval for Tykerb (lapatinib) to include postmenopausal women with hormone- and HER2-positive advanced breast cancer who require hormone therapy.
The new approval is for Tykerb’s use in combination with a second anti-cancer drug, Femara (letrozole), the agency said in a news release.
In women with HER2-positive breast cancer, those who received Tykerb and Femara more than doubled the time they lived without progression of their cancer, compared with those who received Femara alone (35 weeks versus 13 weeks), the FDA said.
Tykerb, first approved in 2007, is designed to block signals that tumor cells need to grow.
The drug is produced by GlaxoSmithKline.
Related Search
tykerb 2011 statistics,
Leave a Reply
Suggested Posts
Vaccine for metastatic breast, ovarian cancer shows promise The U.S. Food a d Drug Admi istratio has expa ded approval for Tykerb (lapati ib) to i clude postme opausal wome with hormo e- a d HER2-positive adva ced breast ca cer who require hormo e therapy. The ew approval is for Tykerb’s use i combi atio with a seco d a ti-ca cer drug, Femara (letrozole), the age cy said i a ews release. I wome with HER2-positive breast [...]. Posted February 1st, 2010 | 7:20 pm
Fungal Toxins Found in Urine of Young Girls Could Impact Future Risk of Breast Cancer The U.S. Food a d Drug Admi istratio has expa ded approval for Tykerb (lapati ib) to i clude postme opausal wome with hormo e- a d HER2-positive adva ced breast ca cer who require hormo e therapy. The ew approval is for Tykerb’s use i combi atio with a seco d a ti-ca cer drug, Femara (letrozole), the age cy said i a ews release. I wome with HER2-positive breast [...]. Posted February 1st, 2010 | 7:20 pm
Blue Shield of California won’t cover the breast cancer drug Avastin The U.S. Food a d Drug Admi istratio has expa ded approval for Tykerb (lapati ib) to i clude postme opausal wome with hormo e- a d HER2-positive adva ced breast ca cer who require hormo e therapy. The ew approval is for Tykerb’s use i combi atio with a seco d a ti-ca cer drug, Femara (letrozole), the age cy said i a ews release. I wome with HER2-positive breast [...]. Posted February 1st, 2010 | 7:20 pm
Boehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib The U.S. Food a d Drug Admi istratio has expa ded approval for Tykerb (lapati ib) to i clude postme opausal wome with hormo e- a d HER2-positive adva ced breast ca cer who require hormo e therapy. The ew approval is for Tykerb’s use i combi atio with a seco d a ti-ca cer drug, Femara (letrozole), the age cy said i a ews release. I wome with HER2-positive breast [...]. Posted February 1st, 2010 | 7:20 pm
Targeted Therapies in Breast Cancer – Oxford American Pocket Notes The U.S. Food a d Drug Admi istratio has expa ded approval for Tykerb (lapati ib) to i clude postme opausal wome with hormo e- a d HER2-positive adva ced breast ca cer who require hormo e therapy. The ew approval is for Tykerb’s use i combi atio with a seco d a ti-ca cer drug, Femara (letrozole), the age cy said i a ews release. I wome with HER2-positive breast [...]. Posted February 1st, 2010 | 7:20 pm